Oncose Technology

The Company’s novel tumor marker technology is based on glyco-proteomics.

Oncose has developed and will commercialize tumor marker tests that analyze blood and urine samples for specific cancer Glycosignatures, also known as glycoprotein glycoforms. This technology can be applied to virtually all cancers.

Learn about our technology

Colorectal Cancer Diagnostic Progress Report

Management Team



Oncose was formed in August 2001 by three distinguished University of Georgia (“UGA”) professors to leverage decades of research on glycoproteins and cancer. Its two scientific founders, J. Michael Pierce, Ph.D. and J. David Puett, Ph.D., are internationally-recognized researchers in the field of glycobiology, and have developed assays to confirm structural changes in selected glycoproteins that occur during oncogenesis.

The Company’s third founder, Clifton A. Baile, PhD., is an Eminent Scholar at UGA and a successful entrepreneur who has played key roles at a number of biotech start-ups. He currently serves as Oncose’s Chairman of the Board.

Mike Wanner joined Oncose in January 2005 as President and CEO to drive business strategy and accelerate test development and commercialization. He brings to the Company a track record of building biotech start-ups into successful business entities.

Learn about our accomplished management and scientific team